Three SMA mechanisms are formulary-listed in GCC, and newborn-screening expansion is generating 60-80 new gene-therapy candidates a year.
SMA incidence in GCC is estimated at 1:6,000-8,000 live births, well above the global 1:10,000 rate, driven by consanguinity raising the frequency of homozygous SMN1 deletion. Saudi Arabia added SMA to its national newborn-screening programme in 2021, among the first GCC states to do so, with UAE and Qatar following by 2023; screening coverage reached an estimated 90% of Saudi births, 85% in the UAE, and 75% in Qatar by mid-2024, while Oman, Bahrain, and Kuwait remain below 50% and are still implementing. Newborn-screening-identified pre-symptomatic infants are now being treated at KAMC, KFSH&RC, Sidra Medicine, and SKMC, and earlier intervention rates are improving year on year as coverage expands.
All three SMA mechanisms are registered and accessible across GCC. Onasemnogene abeparvovec (Zolgensma), SFDA-registered in 2021 and MOH UAE-registered in 2022, is NPHC-covered for Type 1 and pre-symptomatic newborn-screening-identified infants; NPHC and MOH UAE have negotiated outcomes-based rebate arrangements tied to a 24-month motor-milestone, following the CMS CGTA model precedent, bringing GCC list price to an estimated $1.5-1.8M versus $2.125M in the US. An estimated 60-80 Zolgensma cases occur across GCC annually, combining newborn-screening-identified and symptomatic patients. Nusinersen (Spinraza), SFDA-registered since 2017, remains the standard of care for older, already-symptomatic Type 2/3 patients through ongoing intrathecal maintenance dosing, while risdiplam (Evrysdi), registered in 2022, is gaining share among families who prefer a daily oral to repeated intrathecal administration — reproducing the competitive dynamic the US market saw two to three years earlier.
Approved spinal muscular atrophy agents — GCC, 2024
| Drug (Brand / INN) | Mechanism | Company | GCC Registration | Key Trial Result | GCC Access Status |
|---|---|---|---|---|---|
| Zolgensma (onasemnogene abeparvovec) | One-time gene therapy IV | Novartis Gene Therapies | SFDA 2021; MOH UAE 2022; NPHC covered | 91% event-free (STR1VE/NURTURE) | NPHC-listed for Type 1 and NBS-identified pre-symptomatic; outcomes-based rebate terms; ~$1.5-1.8M GCC WAC |
| Spinraza (nusinersen) | Intrathecal ASO, q4m maintenance | Biogen | SFDA registered 2017 | SoC evidence base (ENDEAR/CHERISH) | Widely available; SoC for older Type 2/3 patients; ~SAR 380,000/dose |
| Evrysdi (risdiplam) | Oral SMN2 splicing modifier | Roche | SFDA 2022; MOH UAE 2022 | Oral SoC evidence base (FIREFISH/SUNFISH) | Available; growing share among families avoiding intrathecal dosing; ~SAR 700,000-800,000/year |
Sources: SFDA and MOH UAE registration records; NPHC programme documentation 2023; STR1VE/NURTURE (Zolgensma); ENDEAR/CHERISH (nusinersen); FIREFISH/SUNFISH (risdiplam); Al-Jasmi F et al. Orphanet J Rare Dis 2016; Saudi NBS Programme annual report 2022-2023; Novartis GCC access communications 2022.
What this brief answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- Outcomes-based contract structure vs the CMS CGTA precedent
- motor-milestone assessment criteria
- GCC list-price differential vs US
Delivers
- Country-by-country NBS coverage rates and rollout timelines
- centre readiness (KAMC, KFSH&RC, Sidra Medicine, SKMC)
- volume-forecasting implications
Delivers
- Nusinersen vs risdiplam prescribing-share dynamics
- intrathecal-vs-oral preference drivers
- positioning lessons for any fourth SMA mechanism entering GCC
Custom brief delivered in 72 hours.
Commission This BriefWhat's inside
- Why GCC SMA incidence of 1:6,000-8,000 live births, well above the global 1:10,000 rate, traces to consanguinity raising homozygous SMN1 deletion frequency.
- How Saudi Arabia's 2021 newborn-screening rollout, followed by UAE and Qatar by 2023, left coverage split between 90% in Saudi Arabia and under 50% in Oman, Bahrain, and Kuwait.
- Zolgensma's 91% event-free survival result from STR1VE/NURTURE against Spinraza's ENDEAR/CHERISH base and Evrysdi's oral FIREFISH/SUNFISH data.
- How three companies, Novartis Gene Therapies, Biogen, and Roche, each registered a distinct SMA mechanism in GCC between 2017 and 2022.
- Why NPHC covers Zolgensma specifically for Type 1 and newborn-screening-identified pre-symptomatic infants, while symptomatic Type 2/3 patients default to nusinersen maintenance.
- How risdiplam's daily oral dosing is winning share against nusinersen's intrathecal maintenance among families with an already-diagnosed, symptomatic child.
- How NPHC and MOH UAE's rebate arrangement, tied to a 24-month motor-milestone and modeled on the CMS CGTA precedent, brings Zolgensma's GCC price to $1.5-1.8M against $2.125M in the US.
- Why an estimated 60-80 Zolgensma cases occur across GCC annually, combining newborn-screening-identified and symptomatic patients, under these outcomes-based terms.
- The screening-coverage gap running from 90% of Saudi births and 85% of UAE births down to under 50% in Oman, Bahrain, and Kuwait as of mid-2024.
- Why Oman, Bahrain, and Kuwait remain in an implementation phase for SMA newborn screening while Saudi Arabia, UAE, and Qatar already run mature programmes.
- The four centres, KAMC, KFSH&RC, Sidra Medicine, and SKMC, where newborn-screening-identified pre-symptomatic infants are already being treated.
- How earlier-intervention rates at these treating centres are improving year on year as newborn-screening coverage expands across the GCC.
Included with every brief
How AXLRx builds this brief
Prepared by MoatRx analysts.
Every AXLRx brief is built from primary regulatory sources (FDA, SFDA, MOH, ClinicalTrials.gov), peer-reviewed literature, and live payer/formulary policy documentation — not secondary summaries. Findings are independently verified before inclusion.
Spinal Muscular Atrophy GCC CI sources: SFDA and MOH UAE registration records, NPHC programme documentation 2023, STR1VE/NURTURE (onasemnogene abeparvovec), ENDEAR/CHERISH (nusinersen), FIREFISH/SUNFISH (risdiplam), Al-Jasmi F et al. Orphanet J Rare Dis 2016, Saudi NBS Programme annual reports 2022-2023, and Novartis GCC access communications 2022.
- Drug registration and NPHC coverage status verified against SFDA, MOH UAE, and NPHC programme documentation
- Clinical trial results verified against published primary sources (STR1VE/NURTURE, ENDEAR/CHERISH, FIREFISH/SUNFISH)
- Newborn-screening coverage rates verified against Saudi NBS Programme and MOH UAE NBS expansion reporting
- Outcomes-based contracting terms verified against Novartis GCC access communications and NPHC programme documentation
Frequently asked questions
Commission this brief
AXLRx delivers Spinal Muscular Atrophy competitive intelligence for the GCC market, built for pharma and biotech commercial, access, and medical affairs teams. Custom brief in 72 hours.
Use the intake form to specify your indication, geography, and commercial question.
AXLRx analyst confirms scope, comparators, and delivery format.
Research-verified brief in 72 hours with optional analyst readout.